At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, and is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer in combination with exemestane, E2112.
Syndax is also developing SNDX-6352, monoclonal antibody that binds to the ligand binding domain of the CSF-1 receptor, and SNDX-5613, a potent and selective inhibitor targeting the binding interaction of Menin with MLLr.
Syndax is headquartered in Waltham, Massachusetts.